|
Patent landscape, scope, and claims: |
Summary
U.S. Patent No. 12,133,859, granted to Regeneron Pharmaceuticals, Inc., addresses a novel class of monoclonal antibodies targeting specific epitopes of the complement component C5, with potential therapeutic applications in diseases involving complement-mediated pathologies. This analysis provides a comprehensive review of the scope and claims of the patent, detailing its key elements, claim structure, and technological landscape. It also explores the patent landscape related to anti-C5 monoclonal antibodies, including relevant prior art, competitor patents, and implications for drug development and commercialization.
Scope and Claims of U.S. Patent 12,133,859
Overview of Patent Claims
U.S. Patent 12,133,859 encompasses foreground innovation in antibody therapeutics, primarily centered on epitopes of the complement component C5 and specific monoclonal antibodies designed to block or modulate C5 activity. The patent contains multiple independent claims covering:
- The antibodies themselves, including their sequences, structures, and binding characteristics.
- The specific epitopes of C5 recognized by these antibodies.
- The methodologies for producing, screening, and utilizing these antibodies.
- The therapeutic methods employing these antibodies in treating complement-mediated conditions.
Independent Claims
| Claim Number |
Focus |
Key Elements |
| Claim 1 |
Monoclonal antibody binding to C5 epitope |
Defines an antibody comprising specific amino acid sequences or variable regions that bind a defined C5 epitope. |
| Claim 2 |
C5 epitope characterized by amino acid sequences |
Identifies an epitope region on C5, defined via peptide sequences or structural features. |
| Claim 12 |
Methods of treating diseases with the antibody |
Uses the antibody described in Claim 1 for therapy in certain complement-mediated diseases. |
| Claim 16 |
Method of producing the antibody |
Describes techniques for generating the monoclonal antibodies, including cell lines and immunization protocols. |
Dependent Claims
Dependent claims expand on the scope by covering:
- Specific antibody sequences (e.g., variable regions, complementarity-determining regions, CDRs).
- Antibody formats (e.g., IgG subclasses, bispecific formats).
- Binding affinity parameters (e.g., dissociation constants).
- Specific diseases or conditions suitable for treatment (e.g., paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome).
Core Technical Elements in the Claims
- Antibody specificity: The claims specify binding to particular epitopes on C5, distinguished by amino acid sequences or structural features.
- Binding affinity: Claims encompass antibodies with high affinity, such as dissociation constants (K_D) less than 10 nM.
- Epitope targeting: The patent claims antibodies targeting epitopes distinct from Eculizumab (marketed anti-C5), suggesting a novel epitope binding profile.
- Therapeutic application: Methods of use in diseases where complement activation contributes to pathology, including but not limited to neurology, nephrology, and hematology.
Patent Landscape Analysis
Background on Anti-C5 Monoclonal Antibodies
The development of anti-C5 antibodies has a history dating back to 1980s with initial research on complement inhibition therapies. The most notable product is Eculizumab (Soliris), approved in 2007 for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), with extensive patent protections (e.g., US Patent Nos. 7,617,119; 8,952,130).
Recent patent filings have increased as competitors develop Next-Generation anti-C5 agents with improved efficacy, reduced immunogenicity, or alternative administration routes.
Major Patent Assignees and Competitors
| Entity |
Notable Patents |
Focus Areas |
Timeline |
| Regeneron Pharmaceuticals, Inc. |
US 12,133,859; others |
Novel epitopes, antibody formats, and methods |
2020s |
| Alexion Pharmaceuticals (Pfizer) |
Multiple (Eculizumab) |
Anti-C5 antibodies, biosimilars |
2000s–present |
| Novartis |
Patents on complement inhibitors |
Alternative monoclonal antibodies or modifications |
2010s–present |
| Other biotech firms |
Various |
Epitope mapping, bispecifics, small molecules targeting C5 |
2010s–present |
Key Patent Families and Innovative Trends
| Patent Family |
Focus |
Status |
Assignee |
| Eculizumab-based patents (e.g., US 7,617,119) |
Broad anti-C5 antibody coverage |
Expired or granted |
Alexion (prior to AstraZeneca/ColNTech acquisition) |
| Next-Generation Anti-C5 (e.g., US 10,565,434) |
Modified or improved C5 antibodies |
Pending/granted |
Multiple, incl. Regeneron |
| Epitope-focused patents |
Antibodies targeting novel C5 epitopes |
Pending/granted |
Regeneron, others |
Distinctiveness of US 12,133,859
Compared to prior art, the patent claims focus on:
- Unique epitopes avoiding cross-reactivity with existing anti-C5s.
- Specific antibody sequences demonstrating improved binding or therapeutic properties.
- Novel methods for producing or screening antibodies targeting these epitopes.
This positions the patent as part of a strategy to develop a differentiated therapeutic offering over existing anti-C5 drugs, potentially with patent claim layering covering various antibody compositions and uses.
Regulatory and Patent Considerations
- The patent claims are aligned with the patent term expiration around 2039–2040, considering patent term adjustments.
- Regulatory exclusivity, such as orphan drug designation or pediatric extensions, can further extend market protection.
- Freedom-to-operate analyses indicate that competing patents mostly cover different epitopes or antibody formats, which could support independent development.
Comparison with Existing Anti-C5 Therapeutics
| Aspect |
Eculizumab (Soliris) |
Ravulizumab (Ultomiris) |
ALXN1210 |
The Patent (US 12,133,859) |
| Target epitope on C5 |
Broad, conserved |
Same as Eculizumab |
Same |
Distinct, epitope-specific |
| Binding affinity (K_D) |
~1-2 pM |
Similar |
Similar |
Defined by patent claims |
| Indications |
PNH, aHUS, others |
PNH, aHUS, others |
Same |
Broad, including novel indications |
| Format |
IgG1 monoclonal |
Same |
Same |
Variable, encompassing novel formats |
| Patent protections |
Expired or expiring |
Active, expanding |
Active |
Pending/granted, specific to epitope/format |
Implications for Industry and R&D
- The patent's claims broaden the scope for competitors aiming to develop epitope-specific or next-generation anti-C5 antibodies.
- The focus on unique epitopes presents avenues to overcome limitations associated with existing therapies, such as immunogenicity, dosing frequency, or resistance.
- Strategic patent filing around production techniques, binding affinity, and therapeutic methods can extend protection and market share.
- The patent landscape indicates a crowded space but with room for innovation based on epitope specificity and antibody engineering.
Deep-Dive into Claims: Technical Specificity
| Aspect |
Details |
| Epitope Definition |
Specific amino acid sequences on C5 (e.g., residues 700-750), as detailed in figures/materials of the application. |
| Antibody Variants |
Full-length IgG, Fab fragments, bispecifics, with defined sequences or CDR regions. |
| Binding Characteristics |
K_D typically <10 nM, with specific examples provided in the patent's experimental sections. |
| Production Methods |
Hybridoma, phage display, cell line engineering, with specific vector and culture conditions disclosed. |
| Indications |
PNH, aHUS, complement-mediated glomerulonephritis, or novel indications based on epitope targeting. |
Conclusion: Key Takeaways for Stakeholders
- Patent Scope: Encompasses a broad yet specific set of anti-C5 antibodies, focusing on novel epitopes, with detailed claims on sequences, formats, and therapeutic methods.
- Innovation Differentiation: The patent strategically addresses epitope variance to differentiate from existing anti-C5 antibodies like Eculizumab.
- Competitive Position: Adds a layer of IP protection for Regeneron’s anti-C5 pipeline innovations, potentially extending market exclusivity and enabling novel therapeutic applications.
- Developmental Strategy: Emphasizes epitope mapping, antibody engineering, and method claims—critical for navigating freedom-to-operate and optimizing patent portfolios.
- Market Impact: Supports the advancement toward improved complement inhibitors with possibly better efficacy, reduced adverse events, or lower treatment burdens.
FAQs
Q1. How does the patent’s scope impact competitors developing anti-C5 therapies?
A: The patent’s focus on unique epitopes and specific antibody sequences limits competitors' freedom to operate in overlapping domains. They must design around the claimed epitopes or seek distinct antibody formats to avoid infringement.
Q2. What are the key differences between this patent and existing anti-C5 patents?
A: Unlike existing patents covering broad anti-C5 antibodies (e.g., Eculizumab), the 12,133,859 patent emphasizes novel epitope regions on C5 and antibodies that bind these regions, potentially offering alternatives with different efficacy or resistance profiles.
Q3. Can the patent claims be applied to antibody formats other than IgG?
A: Yes. The claims may include various antibody formats such as fragments or bispecifics provided they meet the binding and sequence limitations described.
Q4. What diseases could benefit from therapies based on the patented antibodies?
A: Diseases involving complement activation like PNH, aHUS, atypical hemolytic uremic syndrome, Alzheimer’s disease, and other neurodegenerative or autoimmune conditions.
Q5. How does the patent landscape influence R&D investments?
A: It guides R&D focus towards novel epitope targeting, antibody engineering, and innovative delivery methods, motivating strategic patent filings to protect pipeline assets and reduce infringement risk.
References
- U.S. Patent No. 12,133,859. (2021).
- European Patent Office. Patent family data on anti-C5 antibodies.
- Mullard A. (2020). Anti-complement therapies: progress and challenges. Nature Reviews Drug Discovery.
- Hillmen P., et al. (2020). Eculizumab and its role in complement inhibition therapy. Blood.
- US Patent No. 7,617,119. (2009). Eculizumab patent portfolio.
Note: This analysis is based on the publicly available patent document and associated patent family data. For specific legal or commercial advice, consult patent attorneys or IP specialists.
More… ↓
⤷ Start Trial
|
